At DanCann Pharma's Annual General Meeting on Wednesday 27 April 2022, Tue Østergaard, CEO of HC Andersen Capital, was elected to the Company's Board of Directors.

In connection with the election to the Board of Directors, Carsten Trads was able to welcome Tue Østergaard. The experienced investment profile, who is CEO of the fast-growing HC Andersen Capital, has in a very short time engaged himself as an investor, founder, advisor, mentor and board member in a number of companies with new, innovative technologies and business models. And according to the chairman of the Board of Directors, he has the right profile in terms of bringing valuable experience and constructive ideas into DanCann Pharma.

Tue Østergaard, new Member of the Board at DanCann Pharma, comments:

- I am very much looking forward to joining the Board of Directors in DanCann Pharma. I fully support DanCann Pharma's vision and the exciting, ambitious growth journey that the Company is on - and I look forward to contributing any way I can. I got to know the Company over the last year, and I am very impressed with how far DanCann Pharma has come in a relatively short time.

Carsten Trads, Chariman of the Board of Directors at DanCann Pharma, comments:

- With his many years of experience at management level and with management and board roles in several companies, Tue has the necessary expertise to contribute to the further development of DanCann Pharma's business. We are thus working intensely to strengthen the Company both at board level and in the organization, where we have succeeded in attracting strong profiles to important functions. At the same time, we enjoy great support from our now extensive circle of more than 4.000 investors.

DanCann Pharma's founder and major shareholder Jeppe Krog Rasmussen has chosen not to stand for re-election to the Board of Directors in order to make a professional separation between the work of the Executive Management team and the Board of Directors.

Jeppe Krog Rasmussen, CEO and former Member of the Board at DanCann Pharma, comments:

- It has been a huge educational process to be in the Board of Directors and I will continue to sit at the board table as the Company's CEO - and will of course continue to be heard as the Company's largest shareholder and founder of the Company. That said, I also feel a responsibility to draw a professional line between the Executive Management team and the Board of Directors. DanCann Pharma has reached a certain size, and has today a large circle of investors, and therefore the Board of Directors must be able to make the best and most objective decisions for the Company with input from the Executive Management team.

After the general meeting, the new Board of Directors constituted itself with Carsten Trads as chairman, Christian Carlsen as vice-chairman and Magnus Østergaard Dahlmann, Per Wester and Tue Østergaard as Board Members.

Disclaimer

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.
For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com